Category Archives: BioEngineering

While biotech stocks are often too risky for many investors, with the coronavirus raging and the race for a vaccine in play, taking a look at some ETFs that contain biotech stocks that are making strides might not be such a bad idea.

With the COVID-19 pandemic raging, biotechs that are consistently profitable and that offer drugs that patients absolutely must have could be seen as relatively safe compared to many other stocks on the market. For investors looking to stay in the market and diversify portfolios, here are two biotech ETFs that could be worth diversifying into during the coronavirus crisis.

With biotech companies like Gilead Sciences, which has been in the news a lot recently for the antiviral drug remdesivir, which appears to be the most promising treatment for COVID-19, IBB is a place for biotech investors to consider. Gilead is conducting late-stage studies of the drug and could report initial results as early as April. Gilead also has adividend yield currently stands at nearly 4%. The company has even augmented its dividend by 58% over the last five years.

IBB seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

While the iShares Genomics Immunology and Healthcare ETF has no directly related coronavirus drug-making companies in its holdings, it does contain stocks like Exelixis, which makes drugs that are used to treat kidney, liver, and medullary thyroid cancer, which will continue to be important going forward. The fund seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

For more market trends, visitETF Trends.

Read the rest here:
2 Biotechnology ETFs That Could Be Good For Diversification - ETF Trends

VILLANOVA Villanova University President the Rev. Peter M. Donohue, OSA, PhD, today announced the appointment of Michele Marcolongo, PhD, PE, as the Drosdick Endowed Dean of the College of Engineering, effective July 31. Dr. Marcolongos engineering career spans more than three decades and encompasses roles as an academician, researcher, administrator, inventor and entrepreneur. This key appointment is the result of a rigorous national search led by a committee of faculty, administrators, students and alumni.

On behalf of the entire Villanova community, I am delighted to have Dr. Marcolongo spearheading our College of Engineering, said University President the Rev. Peter M. Donohue, OSA, PhD. Dr. Marcolongo is a well-known and respected leader whose wide-ranging experience made her stand out in a pool of very talented candidates. I am pleased that she is joining Villanova and that the College of Engineerings students, faculty, staff and alumni will have such a talented and experienced leader at the helm. I look forward to formally welcoming her to our University community.

A faculty member at Drexel University College of Engineering for more than 20 years, Dr. Marcolongo has held numerous leadership positions at the university and college levels. She has served as associate vice provost for Research, senior associate vice provost for Translational Research and associate dean for Intellectual Property Development. In 2018, Dr. Marcolongo was appointed co-chair of the universitys strategic plan, leading a committee of university leaders charged with setting the vision and focus for the next decade of innovative education at Drexel. She is currently department head and professor of Materials Science and Engineering in the College of Engineering.

It is a tremendous honor and privilege for me to be named Drosdick Endowed Dean of the College of Engineering, said Dr. Marcolongo. The Villanova College of Engineering is outstanding in its education of world-class engineers who are technically strong and who have a broad liberal arts background to contextualize real-world solutions for the needs of society. This approach, along with the creative research and scholarship, is what drew me to Villanova. I look forward to working with the community to continue to innovate Villanovas contributions to our world.

Dr. Marcolongos extensive research focuses on biomaterials and engineered biomedical solutions to treat disease. Widely recognized for her expertise and innovative work, she was named a fellow of the National Academy of Inventors and the American Institute for Medical and Biological Engineering. Her research has been funded by such agencies as the National Science Foundation (NSF), the National Institutes of Health (NIH), the US Department of Defense and the US Department of Education. Dr. Marcolongo serves on the editorial boards of two publicationsthe Journal of Biomedical Materials Research and Regenerative Engineering and Translational Medicineand is the founding president of the Philadelphia Spine Research Society.

Our search for a new Dean centered on finding an individual who champions innovative teaching and scholarship, appreciates the opportunities of engineering to positively impact society, and has extensive experience working with major research corporations and agencies, said University Provost Patrick G. Maggitti, PhD. Dr. Marcolongo brings all of these qualities, along with a steadfast commitment to supporting our world-class faculty and students to reach their full potential. I am confident that with Dr. Marcolongo at the helm, the College of Engineering will continue to build upon its storied legacy.

A staunch proponent of the teacher-scholar model, Dr. Marcolongo advised or mentored more than 200 graduate and undergraduate students at Drexel while pursuing her research. She was an integral part of the team that developed Drexels innovative first-year undergraduate engineering curriculum, and she received the Drexel College of Engineerings Teaching Award in 2003. She also is a longtime advocate for inclusivity in engineering education, supporting and mentoring female faculty and graduate and undergraduate students in STEM.

In addition to her extensive work in academia, Dr. Marcolongo is a successful entrepreneur who has co-founded three biomedical technology startup companies and is a co-holder of 15 patents/patent applications. Inspired by her experiences in academia and entrepreneurship, she authored a book, Academic Entrepreneurship: How to Bring Your Scientific Product to a Commercial Discovery, which serves as a how-to guide for academic faculty, graduate students and post-doctorals on translating research from the lab to commercialization.

Prior to joining Drexels faculty, Dr. Marcolongo was a biomedical engineer at DePuy DuPont Orthopaedics, a role in which she invented, designed and tested medical devices. She began her career at General Electric Aerospace. Dr. Marcolongo earned a Bachelor of Science in Mechanical Engineering from the University of Delaware; a Master of Science in Mechanical Engineering from Drexel; and a Master of Science and PhD in Bioengineering from the University of Pennsylvania.

As the Drosdick Endowed Dean of the College of Engineering, Dr. Marcolongo will serve as the chief administrator of the College, providing vision and leadership for its long-term strategic and academic planning, faculty research and teaching innovation; strengthening the student experience; promoting community and industry outreach and partnerships; providing financial oversight; and overseeing fundraising and alumni relations.

See the rest here:
Villanova University appoints Michele Marcolongo, PhD, PE, as the Drosdick Endowed Dean of the College of Engineering - Main Line

Fumaric Acid market report: A rundown

The Fumaric Acid markets business intelligence research comprehensively provides a brief of crucial facts consisting of the product catalog, analytical elaboration, and other industry-linked information.

The study also encompass the important aspects linked with the ongoing events such as mergers & acquisitions, new product launches, and synergisms. The study further accords a rigid preliminary for gaining loads of insights that potential buyers can use for ensuring better profits at low capitals. The demonstration of information on market segmentation by type, application, and geography delivers a critical viewpoint of, what manufacturers are seeking for the stipulated timeframe, 2019 2026.

This article will help the Fumaric Acid manufacturers identify the volume inflation prospect with affecting trends.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2280971&source=atm

An in-depth list of key vendors in Fumaric Acid market include:

The following manufacturers are covered in this report:Yantai Hengyuan BioengineeringBartek IngredientsPolyntThirumalai ChemicalIsegenFuso ChemicalsJiangsu Jiecheng BioengineeringChangzhou Yabang ChemicalNIPPON SHOKUBAISealong BiotechnologyChangmao Biochemical EngineeringSuzhou Youhe Science and TechnologyXST Biological

Fumaric Acid Breakdown Data by TypeFood-GradeTechnical-GradeFumaric Acid Breakdown Data by ApplicationFood & BeveragesRosin Paper SizesUnsaturated Polyester ResinAlkyd ResinsOthers

Fumaric Acid Production Breakdown Data by RegionUnited StatesEuropeChinaJapanOther Regions

Fumaric Acid Consumption Breakdown Data by RegionNorth AmericaUnited StatesCanadaMexicoAsia-PacificChinaIndiaJapanSouth KoreaAustraliaIndonesiaMalaysiaPhilippinesThailandVietnamEuropeGermanyFranceUKItalyRussiaRest of EuropeCentral & South AmericaBrazilRest of South AmericaMiddle East & AfricaGCC CountriesTurkeyEgyptSouth AfricaRest of Middle East & Africa

The study objectives are:To analyze and research the global Fumaric Acid capacity, production, value, consumption, status and forecast;To focus on the key Fumaric Acid manufacturers and study the capacity, production, value, market share and development plans in next few years.To focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.To define, describe and forecast the market by type, application and region.To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.To identify significant trends and factors driving or inhibiting the market growth.To analyze the opportunities in the market for stakeholders by identifying the high growth segments.To strategically analyze each submarket with respect to individual growth trend and their contribution to the market.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Fumaric Acid :History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2280971&source=atm

The market study discusses the highlighted segments on the basis of BPS, market share, profit, and other vital factors. Our business report elaborates the impact of various subdivisions to the growth of the global Fumaric Acid market. It also delivers information on key trends associated with the subdivisions covered in the report. This aids market participants to address worthwhile areas of the global Fumaric Acid market. The market research also provides respective analysis on the subdivisions based on absolute dollar opportunity.

The research attempts to answer many questions as follows:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2280971&licType=S&source=atm

Why Choose Fumaric Acid Market Research?

For More Information Kindly Contact:

marketresearchhub.com

Mr. Nachiket Ghumare,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

See the article here:
Fumaric Acid Market Latest Innovations, Drivers and Industry Key Events 2019 2025 - Packaging News 24

While the world is facing a major crisis due to the coronavirus (COVID-19) outbreak, the IIT Guwahati researchers are working to develop a vaccine to provide an active acquired immunity to the infectious disease.

A media report said the Indian Institute of Technology (IIT), Guwahati is also making efforts to develop rapid detection and portable diagnostic kits for various viruses and microorganisms.

The group of IIT Guwahati researchers has been led by Prof Sachin Kumar of the Department of Biosciences and Bioengineering.

The report quoted the institute as informing that to find a solution for the diseases, its researchers are exploring possibilities to clone the immunogenic proteins of SARS-CoV-2 to be used as diagnostics and possible vaccine candidates.

COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Meanwhile, to prevent the spread of the virus, the institute has also developed the prototype of a Faceshield or mask as per the guideline of the World Health Organisation (WHO).

The team has been led by Dr. Supradip Das of the Department of Design.

Informing about this, the IIT Guwahati on its Twitter handle said: @IITGuwahati has developed the prototype of a Faceshield as per the guideline of the @WHO to be used along with other Personal protective equipment. Faculty has plans to #3Dprint up to 100 pieces. congratulations to Dr. Supradip Das, AP, DoD.

According to the media report, IIT Guwahati has also developed hand-sanitisers as prescribed by the WHO and these are being distributed to everyone on the campus of the institute, including visitors.

The researchers group of the Department of Biosciences and Bioengineering in IIT Guwahati earlier developed recombinant vaccines against Japanese encephalitis and classical swine fever virus.

The research was published in the journal Vaccine and Archives of Virology.

Go here to see the original:
IIT Guwahati researchers working to develop coronavirus vaccine! - Northeast Now

Fortunately, the unusual insects, who live on every continent except Antarctica, are readily available as subjects.

"It's a very prevalent invasive species that can be found all throughout California, including right here on campus, Ramirez said. "All of our specimens we study were collected when they're out and about at night around the nearby creek, since they're nocturnal."

Colors are an important part of a stick insects camouflage defense. When these stick insects first hatch, theyre brown. As they mature and go through successive molts, they may change to an array of vibrant colors from light green to a much darker brown.

"Having adults in a variety of colors allows them to occupy and better survive in different parts of a plant, Ramirez said. "Having a darker stick insect may allow it to blend in more with the trunk of a tree or the darker stems of ivy and blackberry. On the other hand, lighter green stick insects have an advantage on greener surfaces such as the bottom of leaves or greener stems of plants."

These differences in color also affect how well they can escape predators. A darker stick insect can use another means of defense behavioral mimicry if it feels threatened. Once it tucks in its limbs, itll fall down to the ground and "look like a dead twig," Ramirez said.

One puzzle Ramirez is trying to solve is why theres such a colorful palette of Indian walking sticks. Theyre parthenogenic, which means the females dont need males to reproduce. They can actually clone themselves.

"So to see a wide variety of different colors in the stick insects is very interesting because if they're clones of the mother they should all be the same exact thing, but they're not," he said.

"That's something that's really interesting to explore and would definitely require more genetic analysis, which we haven't gotten to quite yet. But hopefully someday that'll be possible in the future," he added.

One reason could be due to genetic mutations.

"There are plenty of other species that undergo parthenogenesis such as aphids, species of bees, ants, wasps, flies, and others which all go through similar asexual cloning mechanisms and can have mutations," Ramirez said. "However, these insects contain very little or do not have any noticeable color variation compared to the Indian stick insects."

Ramirez said he hopes to use the CRISPR/Cas9 gene editing tool to try and unlock the mysteries behind the Indian walking stick.

Hes also planning to apply to dental school after he graduates later this year, with the goal of using what hes learned studying walking sticks. His background in genetics and gene editing will help him in emerging fields of research, such as bioengineering human teeth using stem cells.

"This would be revolutionary for dentistry as patients who have lost their permanent teeth could have them replaced," Ramirez said.

See original here:
Walking Sticks Stop, Drop and Clone to Survive - KQED

Cell Therapy Technologies Market Forecast 2020-2030

LONDON, March 25, 2020 /PRNewswire/ -- Consumables, Equipment, System & Software, Cell Processing, Cell Processing Equipment, Single Use Equipment, Cell Preservation, Distribution, Handling, Process Monitoring & Quality Control, Human Cells, Animal Cells, Life Sciences & Research Companies, Research Institutes

Visiongain estimates that the global cell therapy technologies market will grow at a CAGR of 15% in the first half of the forecast period. In 2020, North America is estimated to hold 38% of the global cell therapy technologies market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new201-page reportyou will receive104 tables and 110 figures all unavailable elsewhere.

The 201-page Visiongain report provides clear detailed insight into the cell therapy technologies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/cell-therapy-technologies-market-forecast-2020-2030/#download_sampe_div

Report Scope

Global Cell Therapy Technologies Marketfrom2020-2030

Forecast of the Global Cell Therapy Technologies Market byType of Product: Consumables Equipment:Cell Processing Equipment, Single Use Equipment, Other Equipment System & Software

Forecast of the Global Cell Therapy Technologies byProcess Type: Cell processing Cell preservation, distribution and handling Process monitoring and quality control

Forecast of the Global Cell Therapy Technologies byCell Type: Human cells:Stem cells, Differentiated cells Animal cells

Forecast of the Global Cell Therapy Technologies byEnd User: Life Sciences and Research Companies Research Institutes

This report provides individual revenue forecasts to 2030 for thesenational markets: The US Canada Mexico UK Germany France Italy Spain Japan China India South Korea Singapore Malaysia Russia Brazil Argentina UAE South Africa Nigeria Mexico

Our study discusses the selectedleading companiesthat are the major players in the respiratory inhalers market: GE Healthcare Lonza Group Merck KGaA Terumo Bct, Inc. Thermo Fisher Scientific, Inc. & Other Companies

For the leading companies, we feature product portfolios, business segment breakdowns, recent developments & key expansion strategies etc.

This report discussesfactors that drive and restrainthis market. As well asopportunitiesandchallengesfaced by this market.

This report discusses thePorter's Five Forces Analysisof the Cell Therapy Technologies Market.

Key questions answered by this report: How is the Cell Therapy Technologies Market evolving? What is driving and restraining factors of the Cell Therapy Technologies Market? What are the market shares of each segment of the overall Cell Therapy Technologies Market in 2020? How will each Cell Therapy Technologies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030? How will the market shares for each Cell Therapy Technologies submarket develop from 2021 to 2030? What will be the main driver for the overall market from 2021 to 2030? Will leading national Cell Therapy Technologies Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030? Who are the leading players and what are their prospects over the forecast period? How will the industry evolve during the period between 2020 and 2030?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/cell-therapy-technologies-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

Affymetrix, Inc.AkouosAllCellsApplikon Biotechnology Inc.ATLATL CentreAutolus LimitedBeckman Coulter, Inc.Becton, Dickinson and CompanyBioengineering AGBiological IndustriesBioWa, IncBrammer BioC.R. Bard, Inc.CaridianBCT, IncCell and Gene Therapy Asia Technology CentreCentre for Process Innovation (CPI)CMC Biologics (Asahi Glass Co.)Cobra BiologicsCocoon PlatformCryoportDanaher CorporationDiNAQOR AGEMD Performance MaterialsEMD SeronoEppendorf AGEuropean Molecular Biology Laboratory (EMBL)Finesse Solutions, Inc.Flexsafe RM TXFloDesign SonicsFlowJo, LLCFood and Drug Administration (FDA)Gamida CellG-CON ManufacturingGE healthcareGenScriptInfors HTIntegrated DNA Technologies, Inc.LaVision BioTecLonza Group, GE HealthcareMassachusetts Eye and Ear (MEE)Meissner Filtration Products, Inc.Merck KGaAMerck SeronoMesoblastMilliporeSigmaMiltenyi BiotecNova BiomedicalPall Corporation (Pall)Patheon N.V.Penn State UniversityPharmaCell B.VSartorius AGSartorius Stedim BiotechScinogySelecta Biosciences, IncSiemensSolaris BiotechStafa Cellular TherapyStafaCTStemcell TechnologiesTerumo Bct, Inc. (A Subsidiary of Terumo Corporation)Thermo Fisher Scientific, Inc.Tillotts Pharma AGTranstem LabUniCAR TherapyWorld Courier

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Stem Cell Technologies and Applications Market 2019-2029

Biobanking Market Forecasts 2019-2029

Biologics Market Trends and Forecasts 2019-2029

Global Bioreactors Market 2020-2030

Global Precision Medicine Market Forecast 2019-2029

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

SOURCE Visiongain

See original here:
Visiongain Report Looks at Opportunities Within the $23bn Cell Therapy Technologies Market - PR Newswire UK